View Older Stories View More Recent Stories

Oct 19, 2020 10:06AM AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ™ (upadacitinib) in Atopic Dermatitis
Oct 19, 2020 08:56AM AbbVie Announces Commencement of Registered Exchange Offers
Oct 19, 2020 05:59AM AbbVie (ABBV) Reports VENCLEXTA (venetoclax) Receives FDA Full Approval for Acute Myeloid Leukemia
Oct 16, 2020 07:34PM VENCLEXTA® (venetoclax) Receives FDA Full Approval for Acute Myeloid Leukemia (AML)
Oct 9, 2020 09:00AM Allergan Aesthetics To Present Data From 4 Abstracts At The 2020 American Society For Dermatologic Surgery Virtual Meeting
Oct 7, 2020 08:06AM AbbVie (ABBV) Company, Allergan Aesthetics, Reports Acquisition of Luminera
Oct 7, 2020 08:00AM Allergan Aesthetics, an AbbVie Company, Acquires Innovative Luminera Dermal Filler Business
Oct 6, 2020 08:00AM AbbVie to Host Third-Quarter 2020 Earnings Conference Call
Oct 2, 2020 08:30AM AbbVie to Present New Data From 15 Abstracts at the 2020 Virtual Migraine Trust International Symposium
Sep 28, 2020 08:01AM AbbVie (ABBV) Receives Orphan Drug, Fast Track Designations from FDA for Elezanumab, an Investigational Monoclonal Antibody RGMa Inhibitor, for Treatment of Spinal Cord Injury
Sep 28, 2020 08:00AM AbbVie Receives Orphan Drug and Fast Track Designations from the U.S. Food and Drug Administration for Elezanumab, an Investigational Monoclonal Antibody RGMa Inhibitor, for the Treatment of Spinal Co
Sep 16, 2020 08:00AM Malin Akerman Joins CoolSculpting® and CoolTone™ as U.S. Ambassador for the Allergan Aesthetics Body Contouring Portfolio
Sep 14, 2020 08:00AM Allergan Aesthetics and Skinbetter Science Announce The DREAM Initiative™ To Advance Health Equity and Diversity in Aesthetics
Sep 11, 2020 11:32AM AbbVie (ABBV) to Present New Data From 18 Abstracts at the International Congress of Parkinson's Disease and Movement Disorders
Sep 11, 2020 11:30AM AbbVie to Present New Data From 18 Abstracts at the International Congress of Parkinson's Disease and Movement Disorders®
Sep 11, 2020 09:39AM AbbVie Declares Quarterly Dividend
Sep 4, 2020 07:01AM AbbVie (ABBV), I-Mab (IMAB) Enter into Pact for Differentiated Immuno-oncology Therapy
Sep 4, 2020 07:00AM AbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
Sep 4, 2020 07:00AM AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
Sep 3, 2020 08:00AM AbbVie to Present at the Morgan Stanley Healthcare Conference
Aug 25, 2020 08:45AM AbbVie (ABBV) Submits Regulatory Application to FDA for RINVOQ for Treatment of Adults with Active Ankylosing Spondylitis
Aug 25, 2020 08:45AM AbbVie Submits Regulatory Application to FDA for RINVOQ™ (upadacitinib) for the Treatment of Adults with Active Ankylosing Spondylitis
Aug 25, 2020 08:13AM AbbVie (ABBV), Harvard University Form Research Alliance to Address Emergent Viral Diseases
Aug 25, 2020 08:00AM AbbVie, Harvard University Form Research Alliance to Address Emergent Viral Diseases
Aug 25, 2020 06:33AM Morphic (MORF) Announces that AbbVie (ABBV) Exercises License Option to αvβ6 Integrin Inhibitor Program, Including MORF-720, for Fibrotic Diseases
Aug 25, 2020 06:30AM Morphic Announces that AbbVie Exercises License Option to αvβ6 Integrin Inhibitor Program, Including MORF-720, for Fibrotic Diseases
Aug 12, 2020 05:47PM AbbVie (ABBV) Notes Positive Phase 3 Data of Venetoclax and Azacitidine Combo Published in NEJM
Aug 12, 2020 05:45PM New England Journal of Medicine Publishes Positive Phase 3 Data of Venetoclax Combination in Acute Myeloid Leukemia (AML) Patients
Aug 3, 2020 07:30AM Members Of The COVID R&D Alliance And Quantum Leap Healthcare Collaborative Enroll First Patients In I-SPY COVID Trial
Jul 31, 2020 07:43AM AbbVie Reports Second-Quarter 2020 Financial Results
Jul 29, 2020 08:46AM AbbVie (ABBV) Phase 3 for Atogepant in Migraine Prevention Met Its Primary Endpoint
Jul 29, 2020 08:45AM AbbVie Announces Positive Phase 3 Data for Atogepant in Migraine Prevention
Jul 28, 2020 08:46AM AbbVie (ABBV) Reports Third Pivotal Ph. 3 Study Shows RINVOQ (upadacitinib) plus Topical Corticosteroids Improves Skin & Itch Symptoms in Atopic Dermatitis Patients
Jul 28, 2020 08:45AM Third Pivotal Phase 3 Study Shows RINVOQ™ (upadacitinib) Plus Topical Corticosteroids Improves Skin and Itch Symptoms in Atopic Dermatitis Patients
Jul 21, 2020 08:45AM AbbVie (ABBV) Announces RINVOQ Monotherapy Met All Primary and Secondary Endpoints in Second Phase 3 Study for Atopic Dermatitis
Jul 21, 2020 08:45AM RINVOQ™ (upadacitinib) Monotherapy Meets All Primary and Secondary Endpoints in Second Phase 3 Study for Atopic Dermatitis
Jul 9, 2020 06:32PM FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label for the Treatment of Pediatric Patients with Spasticity
Jul 7, 2020 08:00AM AbbVie to Host Second-Quarter 2020 Earnings Conference Call
Jun 26, 2020 06:15AM UPDATE: AbbVie (ABBV) Company, Allergan, and Molecular Partners Receive Complete Response Letter from FDA on Biologics License Application for Abicipar pegol
Jun 26, 2020 01:15AM Allergan, an AbbVie Company, and Molecular Partners Receive Complete Response Letter from FDA on Biologics License Application for Abicipar pegol
Jun 23, 2020 07:33AM AbbVie (ABBV) Reports FDA to Review sNDA for IMBRUVICA (ibrutinib); Seeks to Expand U.S. Label with Long-Term Data in Waldenstrom's Macroglobulinemia
Jun 23, 2020 07:30AM IMBRUVICA® (ibrutinib) Seeks to Expand U.S. Label with Long-Term Data in Waldenström's Macroglobulinemia (WM)
Jun 22, 2020 08:00AM AbbVie (ABBV) Announces RINVOQ Monotherapy Shows Improvement in Skin Clearance and Itch in First Phase 3 Study for Atopic Dermatitis
Jun 22, 2020 08:00AM FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX® (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity
Jun 18, 2020 08:45AM RINVOQ™ (upadacitinib) Monotherapy Shows Improvement in Skin Clearance and Itch in First Phase 3 Study for Atopic Dermatitis
Jun 18, 2020 08:01AM Alpine Immune Sciences (ALPN), AbbVie (ABBV) Announce Option and License Agreement for Development and Commercialization of ALPN-101
Jun 18, 2020 08:00AM Alpine Immune Sciences and AbbVie Announce Option and License Agreement for the Development and Commercialization of ALPN-101
Jun 17, 2020 10:32AM AbbVie Declares Quarterly Dividend
Jun 15, 2020 08:15AM AbbVie (ABBV) Announces FDA Approves JUVEDERM VOLUMA XC for Enhancement of Chin Region
Jun 15, 2020 08:15AM FDA Approves JUVÉDERM® VOLUMA™ XC for Enhancement of the Chin Region
View More Recent Stories View Older Stories